Ryan J. Watts - Jun 1, 2021 Form 4 Insider Report for Denali Therapeutics Inc. (DNLI)

Role
President and CEO, Director
Signature
/s/ Tyler Nielsen, by power of attorney
Stock symbol
DNLI
Transactions as of
Jun 1, 2021
Transactions value $
-$1,125,648
Form type
4
Date filed
6/3/2021, 08:08 PM
Next filing
Jul 6, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DNLI Common Stock Sale -$801K -13.1K -0.59% $60.98 2.22M Jun 1, 2021 See footnote F1, F2, F3
transaction DNLI Common Stock Sale -$171K -2.75K -0.12% $62.09 2.21M Jun 1, 2021 See footnote F1, F3, F4
transaction DNLI Common Stock Sale -$132K -2.1K -0.09% $62.76 2.21M Jun 1, 2021 See footnote F1, F3, F5
transaction DNLI Common Stock Sale -$22.5K -354 -0.02% $63.50 2.21M Jun 1, 2021 See footnote F1, F3
holding DNLI Common Stock 157K Jun 1, 2021 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan.
F2 The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $60.48 to $61.46 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F3 The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee.
F4 The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $61.50 to $62.44 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F5 The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $62.50 to $63.055 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F6 Includes 156,691 restricted stock units.